HIKAL Stock Overview
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal healthcare, biotech, crop protection, and specialty chemicals companies.
Price History & Performance
|Historical stock prices|
|Current Share Price||₹250.40|
|52 Week High||₹742.00|
|52 Week Low||₹212.00|
|1 Month Change||-33.63%|
|3 Month Change||-40.61%|
|1 Year Change||-46.79%|
|3 Year Change||48.52%|
|5 Year Change||86.36%|
|Change since IPO||1,622.94%|
Recent News & Updates
Calculating The Fair Value Of Hikal Limited (NSE:HIKAL)
Does the March share price for Hikal Limited ( NSE:HIKAL ) reflect what it's really worth? Today, we will estimate the...
Hikal (NSE:HIKAL) Is Increasing Its Dividend To ₹1.20
Hikal Limited's ( NSE:HIKAL ) dividend will be increasing to ₹1.20 on 15th of March. Despite this raise, the dividend...
|HIKAL||IN Pharmaceuticals||IN Market|
Return vs Industry: HIKAL underperformed the Indian Pharmaceuticals industry which returned -15.3% over the past year.
Return vs Market: HIKAL underperformed the Indian Market which returned -1.7% over the past year.
|HIKAL Average Weekly Movement||7.6%|
|Pharmaceuticals Industry Average Movement||6.7%|
|Market Average Movement||6.9%|
|10% most volatile stocks in IN Market||9.8%|
|10% least volatile stocks in IN Market||4.5%|
Stable Share Price: HIKAL is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: HIKAL's weekly volatility (8%) has been stable over the past year.
About the Company
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal healthcare, biotech, crop protection, and specialty chemicals companies. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs).
Hikal Fundamentals Summary
|HIKAL fundamental statistics|
Is HIKAL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HIKAL income statement (TTM)|
|Cost of Revenue||₹9.96b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||13.02|
|Net Profit Margin||8.26%|
How did HIKAL perform over the long term?See historical performance and comparison
0.7%Current Dividend Yield
Is HIKAL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HIKAL?
Other financial metrics that can be useful for relative valuation.
|What is HIKAL's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does HIKAL's PE Ratio compare to its peers?
|HIKAL PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: HIKAL is good value based on its Price-To-Earnings Ratio (19.4x) compared to the peer average (38.9x).
Price to Earnings Ratio vs Industry
How does HIKAL's PE Ratio compare vs other companies in the Indian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: HIKAL is good value based on its Price-To-Earnings Ratio (19.4x) compared to the Indian Pharmaceuticals industry average (20.2x)
Price to Earnings Ratio vs Fair Ratio
What is HIKAL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||17.8x|
|Fair PE Ratio||27.1x|
Price-To-Earnings vs Fair Ratio: HIKAL is good value based on its Price-To-Earnings Ratio (19.4x) compared to the estimated Fair Price-To-Earnings Ratio (27.3x).
Share Price vs Fair Value
What is the Fair Price of HIKAL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HIKAL (₹250.4) is trading above our estimate of fair value (₹189.2)
Significantly Below Fair Value: HIKAL is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: HIKAL is good value based on its PEG Ratio (0.9x)
Discover undervalued companies
How is Hikal forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HIKAL's forecast earnings growth (20.6% per year) is above the savings rate (6.7%).
Earnings vs Market: HIKAL's earnings (20.6% per year) are forecast to grow faster than the Indian market (17.5% per year).
High Growth Earnings: HIKAL's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HIKAL's revenue (12.3% per year) is forecast to grow faster than the Indian market (11.5% per year).
High Growth Revenue: HIKAL's revenue (12.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HIKAL's Return on Equity is forecast to be low in 3 years time (16.5%).
Discover growth companies
How has Hikal performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HIKAL has high quality earnings.
Growing Profit Margin: HIKAL's current net profit margins (8.3%) are higher than last year (7.7%).
Past Earnings Growth Analysis
Earnings Trend: HIKAL's earnings have grown by 19.8% per year over the past 5 years.
Accelerating Growth: HIKAL's earnings growth over the past year (20.6%) exceeds its 5-year average (19.8% per year).
Earnings vs Industry: HIKAL earnings growth over the past year (20.6%) exceeded the Pharmaceuticals industry 9%.
Return on Equity
High ROE: HIKAL's Return on Equity (15%) is considered low.
Discover strong past performing companies
How is Hikal's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: HIKAL's short term assets (₹9.6B) exceed its short term liabilities (₹7.7B).
Long Term Liabilities: HIKAL's short term assets (₹9.6B) exceed its long term liabilities (₹3.8B).
Debt to Equity History and Analysis
Debt Level: HIKAL's net debt to equity ratio (57.6%) is considered high.
Reducing Debt: HIKAL's debt to equity ratio has reduced from 98.8% to 63.2% over the past 5 years.
Debt Coverage: HIKAL's debt is well covered by operating cash flow (43.6%).
Interest Coverage: HIKAL's interest payments on its debt are well covered by EBIT (7.8x coverage).
Discover healthy companies
What is Hikal current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: HIKAL's dividend (0.63%) is higher than the bottom 25% of dividend payers in the Indian market (0.44%).
High Dividend: HIKAL's dividend (0.63%) is low compared to the top 25% of dividend payers in the Indian market (1.9%).
Stability and Growth of Payments
Stable Dividend: HIKAL's dividend payments have been volatile in the past 10 years.
Growing Dividend: HIKAL's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (12.3%), HIKAL's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (96.6%), HIKAL's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sameer Hiremath (47 yo)
Mr. Sameer Hiremath has been Managing Director of Hikal Limited since September 02, 2021. He served as joint Managing Director of Hikal Limited since November 10, 2011 until September 02, 2021 and served a...
CEO Compensation Analysis
Compensation vs Market: Sameer's total compensation ($USD582.48K) is above average for companies of similar size in the Indian market ($USD262.17K).
Compensation vs Earnings: Sameer's compensation has increased by more than 20% in the past year.
Experienced Management: HIKAL's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: HIKAL's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hikal Limited's employee growth, exchange listings and data sources
- Name: Hikal Limited
- Ticker: HIKAL
- Exchange: NSEI
- Founded: 1988
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹28.501b
- Shares outstanding: 123.30m
- Website: https://www.hikal.com
Number of Employees
- Hikal Limited
- Great Eastern Chambers
- Sector 11
- Navi Mumbai
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.